• Views: in the last
  • 42Week
  • 37Month
  • 105Total


  • NJ A4205
  • Requires continued coverage of prescription drugs for certain medical conditions.
Introduced
(10/6/2016)
In Committee
(5/11/2017)
Crossed OverPassedSignedDead/Failed/Vetoed
2016-2017 Regular Session
This bill requires health insurance carriers to provide continued coverage of prescription drugs for covered persons diagnosed with a complex or chronic medical condition or a rare disease. The bill defines "complex or chronic medical condition" as a physical, behavioral, or developmental condition that does not have a known cure or that can be severely debilitating or fatal if left untreated or undertreated. "Rare disease" is defined as any disease or condition that affects less than 200,000 persons in the United States. This bill requires hospital, medical and health service corporations, commercial insurers, health maintenance organizations, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, prepaid prescription service organizations, and plans provided by the State Health Benefits Commission and the School Employees' Health Benefits Commission to provide continued coverage of a prescription drug prescribed for a complex or chronic medical condition or rare disease when the drug: (1) was previously covered by the carrier; and (2) the prescribing provider continues to prescribe the drug for the medical condition or disease, provided the drug is appropriately prescribed, and neither of the following has occurred: · the United States Food and Drug Administration has issued a notice, guidance, warning, announcement, or any other statement about the drug which calls into question the clinical safety of the drug; or · the manufacturer of the drug has notified the United States Food and Drug Administration of any manufacturing discontinuance or potential discontinuance as required by 21 U.S.C. s.356c. The bill further provides that a carrier shall not set forth limitations on maximum coverage of prescription drug benefits; subject the covered person to increased out-of-pocket costs; or move a drug for a covered person to a more restrictive tier, if the carrier uses a formulary with tiers.
Financial Institutions and Insurance
Reported out of Asm. Comm. with Amendments, and Referred to Assembly Appropriations Committee  (on 5/11/2017)
 
 
Date Chamber Action Description
5/11/2017 Assembly Financial Institutions and Insurance Hearing (19:00 5/11/2017 )
5/11/2017 A Reported out of Asm. Comm. with Amendments, and Referred to Assembly Appropriations Committee
1/30/2017 Assembly Financial Institutions and Insurance Hearing (19:00 1/30/2017 )
1/30/2017 Assembly Financial Institutions and Insurance Hearing (10:00 1/30/2017 Committee Room 16, Fourth Floor)
10/6/2016 A Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Date Motion Yea Nay Other
Detail 5/11/2017 Assembly Financial Institutions and Insurance Committee: Reported with Amendments 11 0 2